IP Verse

Pharmaceutical Formulations Comprising 4-{(1 R)-2-[(6-{2-[(2,6-Dichlorobenzyl)Oxy]Ethoxy}Hexyl)Amino]-1-Hydroxyethyl}-2-(Hydroxymethyl)Phenol

Patent No. EP3578169 (titled "Pharmaceutical Formulations Comprising 4-{(1 R)-2-[(6-{2-[(2,6-Dichlorobenzyl)Oxy]Ethoxy}Hexyl)Amino]-1-Hydroxyethyl}-2-(Hydroxymethyl)Phenol") was filed by Glaxo Group on Feb 26, 2009. The application was issued on Jun 26, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ELKINGTON AND FIFEMar 26, 2025ELKINGTON AND FIFE
TEVA PHARMACEUTICALSMar 26, 2025ELKINGTON AND FIFE
AERAMar 24, 2025BARDEHLE PAGENBERG SL
SANDOZJun 27, 2024MAIWALD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3578169

GLAXO GROUP
Application Number
EP19175120A
Filing Date
Feb 26, 2009
Status
Granted And Under Opposition
May 24, 2024
Publication Date
Jun 26, 2024
External Links
Slate, Register , Google Patents